Cancer Vaccine
IMM-101 Immunization for COVID-19 in Cancer Patients
This trial is testing IMM-101, a new treatment that boosts the immune system, on cancer patients. The goal is to see if it can reduce severe respiratory and COVID-19 infections by helping the body fight off these infections better.
Popular Filters
Trials for COVID-19 Patients
mRNA Vaccine
mRNA COVID-19 Vaccines Safety for Previous Vaccine Reactions
This trial is being conducted to see if people who have had bad reactions to COVID-19 vaccines in the past can safely have another dose, or if people with a history of allergies can safely have the vaccine at all.
Immunoglobulin
hIVIG for COVID-19
This trial is for people with recently diagnosed SARS-CoV-2 infection who do not require hospitalization. The goal is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo.
Virus Therapy
CoVLP for COVID-19
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.
Anti-metabolites
Decitabine for COVID-19
This trial tests if the drug decitabine can safely and effectively treat severe lung issues in critically ill COVID-19 patients. Patients will receive either decitabine or standard care. The goal is to see if decitabine helps improve their condition by reducing lung damage.
Trials for PCS Patients
Procedure
BIO 300 Oral Suspension for Post-COVID Syndrome
This trial is testing whether BIO 300 Oral Suspension can improve lung function in patients who were hospitalized for severe COVID-19 and continue to experience post-acute respiratory complications. Patients will be randomly assigned to receive either BIO 300 or a placebo.
Neurostimulation
PENFS for Post-Concussion Syndrome
This trial tests a small device that sends electrical signals through tiny needles on the outer ear to help children with pain, post-concussion symptoms, and post-COVID-19 symptoms. The electrical signals aim to reduce pain and improve brain function by stimulating nerves in the ear. The use of electrical currents for the treatment of disease has been considered since antiquity but it has only been in recent years that suitable devices have been available to scientific investigators to provide stimulation currents for clinical use.
Behavioural Intervention
Technology-Enabled Care Model for Post-COVID Syndrome
This trial is testing a program to help people with long term effects of COVID and other fatigue-inducing illnesses. The goal is to see if the program is effective and how well it works.
Mechanisms of Post COVID-19 Tachycardia Syndrome
This trial tests a device that sends mild electrical signals to the ear to help people with long-term symptoms after COVID-19. It focuses on those who have ongoing issues like a fast heartbeat and dizziness. The device aims to reduce inflammation and improve these symptoms by stimulating a nerve that helps control these functions.
Phase 3 Trials
Immunoglobulin
hIVIG for COVID-19
This trial is for people with recently diagnosed SARS-CoV-2 infection who do not require hospitalization. The goal is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo.
Virus Therapy
CoVLP for COVID-19
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Trials With No Placebo
Behavioral Intervention
Communication Campaign for COVID-19 Vaccine Uptake
This trial will study if using information from wastewater surveillance of COVID-19 can help increase COVID-19 vaccine uptake in New York counties. The study will compare vaccination rates in counties that receive communication campaigns based
mRNA Vaccine
mRNA COVID-19 Vaccines Safety for Previous Vaccine Reactions
This trial is being conducted to see if people who have had bad reactions to COVID-19 vaccines in the past can safely have another dose, or if people with a history of allergies can safely have the vaccine at all.
Behavioral Intervention
Stepped Alcohol Intervention for Alcohol-related Liver Disease
This trial is testing a new way to help people with chronic liver disease who have unhealthy alcohol use. The new treatment includes 3 sessions of motivational interviewing, and referral to addiction medicine if necessary. The trial will measure how well the new treatment works at 6 and 12 months.
Trials Offering Remuneration
Virus Therapy
mRNA Vaccine Doses for COVID-19
This trial is testing a new COVID-19 vaccine on healthy adults who have already been vaccinated. The goal is to see if it can safely boost their immune response. The vaccine works by using genetic material to help the body recognize and fight the virus.
Virus Therapy
Trivalent Coronavirus Vaccine VBI-2901a for COVID-19
This trial tests a new vaccine, VBI-2901a, aimed at protecting against three coronaviruses, including COVID-19. It targets adults aged 18 to 64 who have previously been vaccinated. The vaccine works by using virus-like particles to boost the immune system's response.
Virus Therapy
Aerosolized Adenovirus COVID-19 Vaccines for COVID-19
This trial tests two new vaccines on healthy people who have previously received COVID-19 vaccinations to see if their immune response can be improved. The vaccines use a harmless virus to deliver parts of the COVID-19 virus, helping the body recognize and defend against it.
Virus Therapy
NDV-HXP-S Vaccine for COVID-19
This trial will test a new vaccine for COVID-19 that is given either in the nose or in the arm. The vaccine is made from a live virus that has been modified to express the spike protein of SARS-CoV-2. The trial will compare two different doses of the vaccine and will also test a placebo vaccine.
View More Related Trials
Frequently Asked Questions
Introduction to coronavirus
What are the top hospitals conducting coronavirus research?
As the world continues to grapple with the ongoing COVID-19 pandemic, hospitals are playing a crucial role in conducting clinical trials to find effective treatments and vaccines. Among these institutions is the University of Michigan in Ann Arbor, which has embarked on two active coronavirus trials, marking an important step forward in combating this global crisis. Having recorded its first trial in 2020, the university is dedicated to exploring innovative approaches to tackle the virus head-on. Meanwhile, Grady Health System in Atlanta has one ongoing coronavirus trial underway. While they may not have conducted any previous trials specifically focused on COVID-19, their involvement signifies their commitment to contribute towards finding solutions for this unprecedented health challenge.
In Atlanta itself, other hospitals are also actively engaged in advancing our understanding of and response to COVID-19. Emory University Hospital Midtown has initiated one current coronavirus trial along with having accomplished a single prior investigation since recording its inaugural coronavirus trial in 2020. Similarly, Emory Hospital and Metro-Atlanta each have one active coronavirus trial but do not possess any completed trials at present.
These hospitals’ dedication demonstrates their pivotal roles as centers of research and innovation during these challenging times. Through rigorous scientific exploration and collaboration among medical professionals across diverse locations like Ann Arbor and Atlanta alike, progress is made toward identifying strategies that will ultimately help us overcome this devastating global pandemic together
Which are the best cities for coronavirus clinical trials?
When it comes to coronavirus clinical trials, several cities emerge as leaders in research and development. Atlanta, Georgia, Houston, Texas, Toronto, Ontario, New york City, and Washington D.C. are among the top locations with active trials. These cities offer individuals access to studies focusing on various treatments such as LDN Treatment Arm and 9vHPV Vaccine in Atlanta; Niclosamide and 700mg Leronlimab in Houston; VBI-2901a and Aspirin Treatment in Toronto; Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) and Stress First Aid in New York City; Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)and 9vHPV Vaccine in Washington D.C. By conducting these trials across different regions, researchers aim to advance our understanding of potential treatment options for COVID-19.
Which are the top treatments for coronavirus being explored in clinical trials?
The race to find effective treatments for the coronavirus continues, with several promising options emerging in clinical trials. Leading the pack is VBI-2901a, currently being tested in one active trial dedicated to fighting this global pandemic. Another contender gaining attention is the 9vHPV vaccine, also undergoing evaluation in one ongoing coronavirus trial. Baricitinib completes the lineup as a potential treatment option, with two all-time trials and one active trial focused on combatting COVID-19 since its first listing in 2020. These innovative therapies offer hope for a brighter future amidst these challenging times.
What are the most recent clinical trials for coronavirus?
Recent clinical trials for coronavirus offer promising prospects in the fight against this global pandemic. These include innovative approaches such as intravenously delivered MSC-exosomes, which are administered every other day on an escalating dose to combat the virus. Additionally, the mRNA-CR-04 vaccine has shown potential in early-phase trials, providing hope for effective immunization strategies. Another trial examines azeliragon's efficacy as a treatment option through its progression from Phase 2 to Phase 3 studies. Furthermore, the mRNA-1045 Dose Level B and VBI-2901a have both entered Phase 1 trials, demonstrating ongoing efforts to discover new therapeutic interventions against coronavirus infection. These cutting-edge clinical investigations signify significant advancements in our collective battle against COVID-19.
What coronavirus clinical trials were recently completed?
Several significant clinical trials for coronavirus have recently reached completion, showcasing the relentless efforts to combat this global health crisis. Notably, in August 2021, Merck Sharp & Dohme Corp. concluded a trial investigating the potential of Molnupiravir as a treatment option. Around the same time, Janssen Vaccines & Prevention B.V.'s trial on Ad26.COV2.S came to an end, examining its efficacy as a vaccine candidate. Additionally, research led by James L. Kirkland explored Fisetin's potential against COVID-19 and was completed in July 2021. These trials represent critical steps forward in our ongoing battle against the pandemic and demonstrate the dedication of researchers worldwide towards finding effective solutions.